Zydus’ Nesher Pharma gets USFDA nod to market generic ADHD drug

PTI New Delhi | Updated on July 19, 2019

Cadila Healthcare on Friday said Zydus’ Nesher Pharmaceuticals has received final nod from the US health regulator to market generic version of Adderall XR capsules in the US.

The final approval from the USFDA is to market Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate extended-release capsules in the strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg, Cadila Healthcare said in a filing to BSE.

The product is a generic version of Adderall XR capsules and will be manufactured at Nesher Pharmaceuticals’ manufacturing facility at St Louis in the US, it added.

The drug is indicated for the treatment of attention-deficit hyperactivity disorder (ADHD), it said.

The group now has 269 approvals and has so far filed over 360 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.

Shares of Cadila Healthcare closed at Rs 228.45 per scrip on BSE, down 1.10 per cent from the previous close.

Published on July 19, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor